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Abstract
Objective
Positive mood on the day of vaccination has been associated with subsequent
antibody responses to the influenza vaccine in older adults. The primary aim of this trial was
to examine whether a brief intervention was able to enhance positive mood at the time of
vaccination in a clinical context. Secondary aims included exploratory analyses of the effects
of the intervention on non-specific and influenza-specific immunity.
Methods
One hundred and three older adults (65-85 years) participated in a two-arm, parallel,
single-blind, randomised controlled trial. Participants viewed either a 15-minute video
package designed to induce positive mood or a matched neutral control video, immediately
prior to receiving a standard dose quadrivalent influenza vaccination. State affect and
secretory IgA levels were assessed immediately prior to, and following, the interventions.
Antigen-specific IgG responses to the vaccination were assessed at 4 and 16-weeks post-
vaccination.
Results
The positive mood intervention resulted in significant improvements in state positive
affect, compared with the neutral control. Secretory IgA levels significantly increased across
both groups. Antigen-specific IgG responses to influenza vaccination were not statistically
significantly different between groups, although point-estimates of effect size favoured
participants who viewed the positive mood intervention for most strains at both 4 and 16-
weeks post-vaccination.
Conclusions
A 15-minute intervention can improve positive mood in older adults prior to
vaccination. Future trials should examine whether enhancing mood at the time of vaccination
could enhance the effectiveness of influenza vaccination on patients and benefit health
services.
Keywords: Positive affect, intervention, positive mood, vaccination, immunity,
psychoneuroimmunology
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03144518
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The protection afforded by the annual seasonal influenza vaccination is considerably
lower in older adults compared to younger adults (Goodwin, Viboud, & Simonsen, 2006), in
part due to age-related declines in immunological competence (Reber et al., 2012). This
leaves older adults at an increased risk of the most serious complications associated with
influenza infection, with 90% of influenza-related deaths in industrialised countries occurring
in those aged over 65 years (Thompson, Shay, & Weintraub, 2003). To date, advances to
improve influenza vaccine responses in older adults have primarily focused on
pharmacological solutions. These have met with some success with adjuvanted influenza
vaccines, that contain an additional component that stimulates a heightened immune
response, and high-dose vaccines, that include a four times greater amount of each influenza
antigen, showing improved protection in older adults in recent years (DiazGranados et al.,
2014; Domnich et al., 2017). However, even with the increasing adoption of these enhanced
vaccine formulations, reduced vaccine efficacy in older adults remains problematic. For
example, the adjuvanted trivalent (i.e., containing three strains) influenza vaccine adopted by
many countries for the most recent influenza season (2018/19), was reported to have an
estimated effectiveness of around 51% against hospitalisations for influenza/pneumonia in
community dwelling older adults (Domnich et al., 2017). This indicates calls to research and
develop novel approaches to improve vaccine responses in this population (e.g., Kelly &
Valenciano, 2012; Lang, Govind, Mitchell, Siegrist, & Aspinall, 2011; Lang et al., 2012)
remain highly relevant.
One alternative to enhancing vaccine responses in older adults are psychological and
behavioural interventions. Psychological and behavioural factors have been shown to
influence the dynamics of the immune system, in turn modifying responses to antigenic
challenge (e.g., Calder, 2013; Pascoe, Fiatarone Singh, & Edwards, 2014; Pedersen,
Zachariae, & Bovbjerg, 2009; Prather et al., 2012). To give some examples: chronically
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stressed older adult spousal carers show blunted immune responses to influenza vaccination
compared to age-matched non-carers (Kiecolt-Glaser, Glaser, Gravenstein, Malarkey, &
Sheridan, 1996; Vedhara et al., 1999); a single night of sleep deprivation in young adults
results in a nearly two-fold reduced antibody response to hepatitis A vaccination at 4 weeks
post-vaccination compared to those who sleep normally (Lange, 2003); and salivary antibody
secretions to an orally ingested antigen have been shown in longitudinal studies to be
differentially influenced by both positive and negative life events (Stone, Cox,
Valdimarsdottir, Jandorf, & Neale, 1987; Stone et al., 1994). More recently in a prospective
cohort study examining the effects of multiple lifestyle factors and psychological well-being
on the response to influenza vaccination in older adults (Ayling et al., 2018), we identified
that positive affect, in particular on the day of vaccination, was associated with enhanced
short and long-term antibody responses to the weakest immunogenic strain of the influenza
vaccination.
The mechanisms by which positive affect influences immune function continue to be
elucidated (for reviews of this topic see Dockray & Steptoe, 2010; Marsland, Pressman, &
Cohen, 2007; Pressman, Jenkins, & Moskowitz, 2019). Indirect influences of positive affect
via health behaviours have been shown to impact immune function (e.g., sleep, nutrition,
physical activity). Similarly, direct effects have also been reported via the activation of
neuroendocrine systems responsible for the release of hormones, such as cortisol and
norepinephrine, which in turn interact with immune cells via receptors on their surface
(Marques-Deak, Cizza, & Sternberg, 2005). Further, there are well established anatomical
links between the central nervous and immune systems, including the direct innervation of
lymphatic organs (Felten & Felten, 1991; Nance & Sanders, 2007) that can potentially be
triggered by positive affect. As such there are multiple, biologically plausible mechanisms by
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which a positive affect intervention could influence immunity, and in turn, antibody
responses to vaccination.
In view of previous observational evidence that positive mood on the day of
vaccination is associated with enhanced antibody responses; and the presence of plausible
biological pathways to explain this effect, we designed a study to explore whether we could
enhance positive mood in older people immediately prior to vaccination. The study was a
randomised controlled trial in which participants were randomised to view either a novel
positive mood intervention on a digital platform (15 minutes long) or neutral control material
also 15 minutes in duration and delivered on the same digital platform. Our primary aim was,
therefore, to examine whether our positive mood intervention resulted in greater positive
mood compared with the neutral control. The secondary aims, were to: explore the effect on
an immediate immune parameter (secretory IgA) previously shown to be sensitive to positive
mood inductions (e.g., Pawlow & Jones, 2005; Yamamoto & Nagata, 2011) and vaccine-
specific IgG responses, as a surrogate of vaccine effectiveness. We also examined the
moderating effects of perceived health status and psychological traits on mood and immune
responses to the intervention; and the feasibility of a future definitive trial by examining
participant recruitment levels, attrition, and numbers receiving the intervention as intended.
Method
Study Design
The study was a two-arm, parallel, single-blind, randomised controlled trial conducted
between August 2017 and May 2018. Research governance and ethical approval for this
study was given by the Health Research Authority and East Midlands - Nottingham Research
Ethics Committee 1 (17/EM/0198) prior to study commencement. The study was pre-
registered at clinicaltrials.gov (NCT03144518).
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Participants
One hundred and three older adults (65-85 years) eligible to receive the 2017-18
influenza vaccination participated in the study. Participants were identified through two
primary care practices in Nottingham, UK. Given the influence of prior vaccination history
on subsequent immune responses to vaccination (Sasaki et al., 2008), recruitment was limited
to those who had received the influenza vaccination the previous year (2016/17). The purpose
of this was to minimise between-person differences in previous exposure to influenza and
influenza vaccination and the concomitant effects on antibody levels prior to vaccination.
Alternative approaches including statistically controlling for vaccine history or recruiting
only participants who had not previously received an influenza vaccination were rejected due
to concerns with poor record keeping and reduced generalisability respectively. Exclusion
criteria were kept minimal to maximise generalisability. They included: deemed by health
care provider to be too physically frail to participate; diagnosed with a cognitive condition
(e.g., dementia) that would make participation difficult; to have insufficient command of the
English language; being sufficiently impaired of hearing or vision that exposure to the
intervention or neutral video content as intended would be compromised; or having a
contraindication for influenza vaccination or venepuncture.
Randomisation
Randomisation to condition was done using a computer-generated block
randomisation sequence (block size = 10) on a 1:1 allocation ratio, initiated by the lead author
(KA). This randomly generated sequence was matched to participant ID numbers (assigned in
order of response to invitation letter) in such a manner that touchscreen computer tablets were
programmed to play either the positive mood or neutral control content, without the
researchers being aware of participant assignment.
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Procedure
Eligible patients at each primary care practice were sent an invitation letter detailing
the study and providing researcher contact details. Participants were informed the purpose of
the study was to explore the effects of mood on influenza vaccination and that they would be
asked to watch a short video. They were not told that there were positive mood and neutral
control conditions. Interested individuals contacted the research team via email, telephone, or
by returning a reply slip provided with a freepost envelope. After discussing the study with
the researchers, those who agreed to participate were sent a detailed information sheet,
consent form, and baseline questionnaire to complete and return via post. This questionnaire
included sections on demographic information, perceived health status, and trait
psychological characteristics related to affective experience.
Participants then attended a session at their local primary care practice (maximum of
six participants per session) where they had a pre-vaccination blood sample taken (8ml),
height and weight measured, and provided a pre-intervention saliva sample for the
measurement of secretory IgA. Participants were then given a demonstration of how to use a
touchscreen computer tablet device (Model: ASUS-T101HA) to complete the state affect
measures, with a small minority opting to complete measures using printed questionnaires
(n=3, 2.9%). Participants then completed pre-intervention measures (approximately 5
minutes) and viewed either the positive mood intervention video or neutral control video on
an individual tablet device wearing over-ear headphones, followed by completion of the post-
intervention measures. For those completing measures on the tablet (presented using
OpenSesame software: Mathot, Schreij, & Theeuwes, 2012) - the order of scale presentation
(and any items within those scales) was randomised to minimise order effects. Participants
then provided a further saliva sample and had a standard dose of the quadrivalent 2017/18
seasonal influenza vaccine administered. The vaccine was administered by a practice nurse or
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health care assistant within five minutes of completing the intervention. Participants returned
for follow-up blood samples at four and 16-weeks post-vaccination. Health-care utilization
attributable to influenza-like symptoms was assessed by the lead author (KA) who consulted
medical records at six months post-vaccination noting any consultations during the prior six
months where influenza-like symptoms were assigned read-codes or noted in free-text entries
(e.g., runny nose, sore throat, fever), antibiotic prescriptions not clearly attributable to another
cause (e.g., urinary tract infection), and where additional investigations related to influenza-
like symptoms were ordered (e.g., chest X-ray). Participants received £20 inconvenience
payments for taking part in the study. Materials and stimuli used in the study can be accessed
at osf.io/u7h36.1
Positive Mood Intervention Condition
Participants in the positive mood condition viewed a video lasting 15 minutes and 30
seconds specifically developed to increase state affect in older adults. Most previous brief
positive affect interventions have been developed for use in young adults and without a
clinical context in mind. The development of the intervention is the subject of a related
manuscript (Ayling et al., in preparation). In brief, the intervention was iteratively developed
following a systematic review of brief interventions that induced positive mood and measured
immunity, qualitative focus groups and interviews with older adults and health care
professionals, and co-development alongside patient and public involvement partners. These
led to some key guiding principles that the intervention should be presented individually,
made up of high arousal stimuli in multiple forms (e.g., uplifting music, images, ‘classic’
comedy) to appeal to different tastes, and be around 15 minutes in duration due to the
constraints of a primary care clinical context. Thus, the resulting intervention was a
1 Please note that while UK copyright laws permitted the limited use of copyright protected works used in the interventions for non-commercial
research purposes in the UK at the time this research was conducted (see https://www.gov.uk/guidance/exceptions-to-copyright), copyright
restrictions may apply in other countries or as a result of subsequent legislation changes in the UK.
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combination of these elements. A description of the specific intervention stimuli and the
intervention itself can be viewed at osf.io/u7h36. Prior piloting of the intervention in older
adults outside of a clinical context indicated that the intervention was successful in inducing
significant positive affect increases assessed on a visual analogue scale of happiness (Kontou,
Thomas, & Lincoln, 2012), and a pictorial scale of positive affect (see below), but not the
positive and negative affect schedule (Watson, Clark, & Tellegen, 1988).
Neutral Control Video
Participants in the control condition viewed a video designed to match key features of
the positive mood intervention video (e.g., length, format), but with neutral emotional
content. For example, videos included documentary and lecture clips, music judged to be
non-emotive, and images with neutral emotional valence from the Nencki Affective Picture
System (Marchewka, Zurawski, Jednoróg, & Grabowska, 2014).
Measures
Baseline/trait measures. Perceived health status was measured using the 12 item
Health Status Questionnaire 2.0 (Barry, Kaiser, & Atwood, 2007). Participants indicated the
extent to which they experienced a variety of health-related difficulties (e.g., “How much
bodily pain have you had during the past 4 weeks?”) on Likert-type scales. Items covered a
broad range of health-relevant domains including physical functioning, social functioning,
bodily pain, and mental health. Responses were weighted in accordance with published
guidelines and summed to calculate a total perceived health status score ( = .91), with
higher scores indicating greater perceived health.
Trait positive and negative affect were measured using the Positive and Negative
Affect Schedule (Watson et al., 1988). Participants were presented with 10 positive (e.g.,
excited) and 10 negative (e.g., ashamed) emotion adjectives, which they were asked to rate
the extent to which they felt that way ‘‘in general” on a five-point scale (“very slightly or not
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at all” – “extremely)”. Positive (α = .92) and negative affect subscales (α = .92) were created
by summing the scores of positive and negative adjectives respectively, with higher scores
indicating greater trait positive and negative affect respectively.
Trait optimism was measured using the Revised Life Orientation Test (Scheier,
Carver, & Bridges, 1994). Participants were asked to indicate the extent to which they agreed
with 10 statements about themselves (e.g. “In uncertain times, I usually expect the best”) on a
five-point scale ranging from “strongly disagree” to “strongly agree”. Four items were filler
questions, with the remaining six used to compute a trait optimism score (α = .73) with higher
scores indicating with greater optimism.
Trait emotional reactivity was measured using the 21-item Emotional Reactivity Scale
(Nock, Wedig, Holmberg, & Hooley, 2008). Participants were asked to indicate the extent to
which they felt particular statements reflect themselves (e.g., “I experience emotions very
strongly”) on a five-point scale ranging from “not at all like me” to “completely like me”.
Items scores were then summed (α = .96), with greater scores indicating greater trait
emotional reactivity.
State affect measures. Prior to, and immediately following, viewing either the
positive mood or neutral control video all participants completed the Affective Slider (Betella
& Verschure, 2016), the state version of the Positive and Negative Affect Schedule (Watson
et al., 1988), and an internally developed pictorial measure of positive affect tailored for older
adults (described below). The primary outcome measure was the Affective Slider, as prior
piloting of the intervention in community samples raised concerns regarding sensitivity of the
Positive and Negative Affect Schedule to acute changes in mood, and the pictorial measure
had not yet gone through robust reliability testing.
Affective slider. Participants were asked to place a mark representing “how you feel
right now, that is, at the present moment”, on two horizontal sliding visual analogue scales
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representing emotional valence and arousal. Each scale was presented with corresponding
cartoon faces depicting high and low levels of pleasure and arousal respectively. Scores range
from 0 to 100 with higher scores indicating greater pleasure and arousal (hereafter referred to
as slider-valence and slider-arousal scores). The Affective Slider has previously been shown
to compare favourably against the Self-Assessment Manikin and be responsive to affective
stimuli (Betella & Verschure, 2016).
Positive and negative affect schedule (PANAS). The state version of this scale
(Watson et al., 1988) consists of 20 emotion adjectives for which participants indicated the
extent to which they felt that way “right now, that is, at the present moment” - on a five-point
scale. Positive (mean α = .89) and negative affect subscales (mean α = .89) were created by
summing the scores of positive and negative adjectives respectively.
Pictorial scale of positive affect. Participants completed a single-item photo-based
measure of positive affect tailored for older adults, the development of which is the subject of
a different manuscript (Ayling et al., in preparation). Participants were presented with six
groups of images (including older adult faces) depicting varying degrees of positive affect,
ranging from neutral to extremely happy. They were then asked to select the group of images
which best reflected “how you feel right now, that is, at the present moment”. Piloting in
community samples showed this scale was sensitive to mood induction, and significantly
positively correlated with the neutral-happy dimension of the revised Visual Analogue Mood
Scale (Kontou et al., 2012), and the state version of the PANAS positive affect scale.
Immune Measures
Antigen specific IgG. Venous blood samples (8 ml) were obtained for the
measurement of IgG antibody levels at baseline, 4 weeks post-vaccination, and 16 weeks
post-vaccination. The rationale for the timings of blood samples was that IgG antibody levels
are at their peak approximately 4 weeks post-vaccination (Gross et al., 1996), whereas 16
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weeks post-vaccination coincides with the anticipated peak of influenza incidence in the UK
(i.e., January-March) at which point sustained high levels of antibody may be of particular
clinical benefit. After clotting at room temperature, samples were centrifuged at 2000g for 10
minutes after which sera were separated and stored at -20°C until analysis. Influenza IgG
antibodies for each of the strains contained in the vaccine were measured via enzyme-linked
immunoassay (ELISA). The following description outlines the protocol used, with aspiration
and washes with three cycles of 80 l 0.05% Tween-20 solution in phosphate buffered saline
(PBS) occurring between each step, with all incubations at room temperature unless
otherwise stated. All samples were analysed in duplicate (samples mean intra-assay CV =
3.97%) with dilutions and pipetting into plates were performed by using a computerised
pipetting system (Precision XS, BioTek) for accuracy.
Antigens (A/Hong-Kong/4801/2014; A/Michigan/45/2015; B/Brisbane/60/2008;
B/Phucket/3073/2013; National Institute of Biological Standards and Control) were diluted to
0.5 gHA/ml, 1 gHA/ml, 0.25 gHA/ml, and 0.25 gHA/ml respectively in carbonate-
bicarbonate buffer with 20 l added to 384-well plates (NUNC MaxiSorp, Thermo Fisher
Scientific). Alongside this, 15 two-fold serial human IgG dilutions (top dilution 2 g/ml;
Merek) were added in duplicate (20 l) to each plate to form a calibration curve and left at
4°C overnight. Wells were then blocked with 40 l of 3% bovine serum albumin in PBS for 1
hour. Sera diluted at 1:4000 in PBS was added in duplicate (20 l) for each antigen for two
hours. PBS was added to the calibration curve for the same period. Following this, 20 l of
biotinylated anti-human IgG (vector labs) diluted to 1:320000 in PBS was added for a further
2 hours. Streptavidin-HRP (R&D systems) diluted at 1:40 in PBS was then added to wells for
15 minutes. Finally, 20 l of tetramethylbenzidine substrate solution (Sigma-Aldrich) was
added to each well for 10 min, before the reaction was stopped with 20 l of 1N sulphuric
acid. Plates were then scanned at 450 nm on a GloMax Explorer instrument (Promega).
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Signals from samples were interpolated from the human IgG calibration curve on each plate,
with a set of 40 repeated samples processed on each plate used to normalise assays run across
different days. Values were then multiplied by the serum dilution score (i.e., 4000) for ease of
data presentation.
Secretory IgA. Unstimulated passive drool saliva samples were obtained immediately
prior to, and following, viewing the positive mood or neutral control video. Participants were
asked to allow saliva to accumulate in their mouth for two minutes, passing saliva into
polypropylene vials through a SalivaBio collection aid (Salimetrics/Stratech). All vials were
weighed before and after saliva collection to determine salivary flow rate. Samples were
stored at -20°C until analysis. Secretory IgA levels were determined using a commercial
indirect ELISA kit, according to manufacturer instructions (see Salimetrics, 2017). Secretory
IgA secretion rate (µg/min) was calculated by multiplying secretory IgA concentration from
the assay by salivary flow rate, divided by the total collection time.
Statistical Analysis
Statistical analyses were performed using IBM SPSS Statistics (version 25) and
GraphPad Prism (version 7). The primary outcome was between group differences in state
affect following the intervention or neutral control video. A priori sample size calculations
indicated a sample of 102 participants would be needed to detect a medium-sized (d=0.5)
between group effect in state affect scores in a one-tailed independent samples t-test with
80% power. A recent meta-analysis we conducted of brief-mood enhancing interventions and
immunity (Ayling et al., under review) suggested that successful brief (i.e., single session)
interventions tend to have an average effect size on mood of around d=0.6, although there
was significant heterogeneity. However, only one of the trials in that review included older
adults and it is not yet established how large a mood effect would have to be to be ‘immune-
relevant’. Given this, we decided a priori that a medium sized effect on mood would be
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comparable to other successful mood manipulations in younger cohorts and thus powered the
trial accordingly. However, given our focus on between group differences we conducted a
series of two-way analyses of variance comparing change in state affect scores across groups.
Normality of distributions were assessed via the examination of histograms, with log2 or
reciprocal transformations used to improve normality where possible if significant skew was
evident. Paired sample t-tests, or non-parametric equivalents were used to explore within-
group effects. The potential influence of trait psychological characteristics on state affect
responses was also explored. This involved a series of multiple regression analyses entering
trait measures individually to predict post-intervention state affect scores controlling for pre-
intervention scores. Those trait measures that significantly predicted post-intervention state
affect scores were entered simultaneously in a further model to test whether they were
independent predictors.
This trial was not a priori powered to detect significant between group differences in
immunological outcomes but to determine if there was early evidence of an effect of the
intervention on immunity and to explore the feasibility of a subsequent, appropriately
powered trial. As such, results for immunological outcomes are primarily presented
descriptively, with inferential tests conducted for the purpose of describing effect sizes. For
secretory IgA outcomes we conducted a two-way analysis of variance comparing change
from pre- to post-intervention between groups. For antigen specific IgG levels we conducted
a series of one-way analyses of covariance comparing between group post-intervention IgG
levels, in order to better control for pre-intervention differences. Given prior findings that
trait psychological characteristics and health status can influence immunological responses to
vaccination (Gross, Quinnan, Weksler, Setia, & Douglas, 1989; Marsland, Cohen, Rabin, &
Manuck, 2006), we explored this across the entire cohort. To do this, a series of multiple
regression analyses predicting post-intervention antigen-specific IgG were conducted
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controlling for pre-intervention IgG levels and condition in step one, with trait psychological
characteristics and health status entered individually in step two. Where multiple significant
predictors were identified they were entered simultaneously in a further model to test whether
they were independent predictors.
As levels of missing outcome data were low (see supplementary appendix) and found
to be missing completely at random (Little’s MCAR test: χ2(237) = 236.12, p = .504), we
performed intention-to-treat analyses with listwise deletion for analyses where follow-up data
were missing. We also performed per-protocol analyses excluding three participants (two
from neutral control group, one from positive mood group) who did not complete study
activities as intended (one was observed putting the tablet down and not watching the
presented stimuli, one was observed watching another nearby participant’s tablet screen, and
one was delayed in receiving their vaccine after completing tablet activities). Nearly all per-
protocol analyses did not result in any differing interpretations of the results presented below,
thus only those which potentially impact on findings are presented here.
Results
Participant Recruitment & Randomisation
Figure 1 shows the flow of participants through the study. Of the 1131 patients invited
to participate, 106 (9.4%) consented. Of these 103 (97.2%) attended the appointment to
receive their vaccination and were randomised to view the intervention or neutral control
video. Retention throughout the study was high, with 102 (96.2%) participants attending
follow-ups at four weeks post-vaccination, and 98 attending follow-ups at 16 weeks post-
vaccination (92.5%). Table 1 shows the baseline characteristics of participants in each group.
Pre-intervention there were no significant differences between groups on any demographic,
psychological, or immunological factors.
Psychological Outcomes
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State affect outcomes. We performed two-way mixed analyses of variance to compare the
effects of the positive mood intervention and neutral control videos on state affect. Pre- and
post-intervention scores on state affect measures can be seen in Table 2. Participants in the
positive mood group had significantly greater improvements from pre- to post-intervention
for slider valence [F(1,98) = 6.97, p = .010, partial η2 = .066, 90% CI (.009, .157)], and
pictorial positive affect scores [F(1,96) = 8.83, p = .004, partial η2 = .084, 90% CI (.017,
.181)] as indicated by significant time by group interactions. There were no statistically
significant time by group interactions for slider-arousal [F(1,98) = 3.36, p = .070, partial η2 =
.033, 90% CI (.000, .108)] or PANAS scores [positive affect: F(1,99) = 0.19, p = .668, partial
η2 = .002 , 90% CI (.000, .039); negative affect: F(1,101) = 0.22, p = .642, partial η2 = .002,
90% CI (.000, .040)].
Paired Wilcoxon signed rank tests examining state affect in the groups individually
showed that following the intervention the positive mood group significantly increased in
slider-valence (Z = -4.21, p < .001, r = .60), slider-arousal (Z = -2.92, p = .003, r = .42), and
pictorial positive affect scores (Z = -3.70, p < .001, r = .53), significantly decreased in
PANAS negative affect scores (Z = -3.95, p < .001, r = -.51), but had no statistically
significant change in PANAS positive affect scores (Z = -1.66, p = .098, r = .23). In contrast,
there were no significant changes in the neutral control group following viewing the video
(Slider-Valence: Z = -.24, p = .810, r = .03; Slider-Arousal: Z = -.11, p = .912, r = -.02;
pictorial positive affect scores: Z = -.13, p = .895 r = -.02; PANAS negative affect: Z = -1.93,
p = .053, r = -.27; PANAS positive affect: Z = -.64, p = .524, r = .09). In per protocol
analyses, the decrease in PANAS negative affect scores in the neutral control group became
statistically significant (Z = -1.99, p = .046).
Influence of trait psychological characteristics on state affect outcomes. Multiple
regression analyses were conducted to examine the influence of trait psychological
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characteristics on state affect responses. Within the positive mood group, higher slider-
valence and slider-arousal scores following the intervention (controlling for pre-intervention
scores) were significantly predicted by lower trait negative affect (slider-valence: β = -.312, p
= .003. Model: F(2, 44) = 40.37, p < .001, R2 = .631; slider-arousal: β = -.348, p = .003.
Model: F(2, 44) = 43.68, p < .001, R2 = .665) and trait emotional reactivity (slider-valence: β
= -.274, p = .008. Model: F(2, 43) = 34.12, p < .001, R2 = .613; slider-arousal: β = -.247, p =
.027. Model: F(2, 43) = 34.14, p < .001, R2 = .614) in separate regression models. Entering
trait negative affect and emotional reactivity into regression models simultaneously indicated
neither were independent significant predictors above pre-intervention scores2. Higher
pictorial positive affect scores following the intervention were significantly predicted by
lower trait negative affect (β = -.438, p = .001. Model: F(2, 43) = 10.92, p < .001, R2 = .337)
and higher trait optimism (β = .305, p = .033. Model: F(2, 44) = 5.70, p = .006, R2 = .206)
when considered separately. However, when entered into the model simultaneously only trait
negative affect was an independent significant predictor (β = -.407, p = .008. Model: F(3, 40)
= 7.61, p < .001, R2 = .316). No trait psychological characteristics significantly predicted
state PANAS outcomes in the positive mood intervention group following the intervention. In
the neutral control group, higher slider-arousal scores following the intervention were
predicted by greater trait positive affect (β = .362, p = .016. Model: F(2, 42) = 6.48, p = .004,
R2 = .236) and higher PANAS negative affect scores following the intervention were
predicted by lower trait positive affect scores (β = -.357, p = .035. Model: F(2, 42) = 4.22, p
= .021, R2 = .17).
Immunological Outcomes
2 In per protocol analysis, for slider-arousal scores only trait negative affect was an independent significant predictor above pre-intervention
scores (β = -.27, p = .048. Model: F(3, 40) = 28.41, p < .001, R2 = .681)
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Secretory IgA. Only 81 participants (37 neutral control group, 44 positive mood group)
produced sufficient saliva for analysis at both pre- and post-intervention. Pre- and post-
intervention s-IgA levels can be seen in Table 2. We conducted two-way mixed analyses of
variance, to compare the effects of the positive mood intervention and neutral control videos
on s-IgA secretion rates. There was no significant time by group interaction in post-
intervention secretory IgA rates [F(1, 79) = .00, p = .996, partial η2 < .001 , 90% CI (.000,
.000)]. There was however a significant main effect of time, such that secretory IgA
increased over time across groups [F(1, 79) = 20.64, p < .001, partial η2 = .207 , 90% CI
(.087, .327)]. Paired sample t-tests examining groups individually revealed secretory IgA
rates significantly increased from pre-video to post-video samples in both positive mood
intervention [t(43) = -3.36, p = .002, d = .51] and neutral control groups [t(36) = -3.08, p =
.004, d = .51].
Influenza-specific IgG. As expected, IgG antibody levels for all strains significantly
increased following vaccination [B/Brisbane: F(2, 192) = 27.78, p < .001, partial η2 = .22 ,
90% CI (.139, .300); B/Phucket: F(1.85, 177.65) = 41.82, p < .001, partial η2 = .30 , 90% CI
(.209, .382); A/Hong-Kong: F(2, 192) = 16.71, p < .001, partial η2 = .15 , 90% CI (.074,
.219); A/Michigan: F(1.74, 165.68) = 36.90, p < .001, partial η2 = .28 , 90% CI (.183, .361)].
Pairwise comparisons (Bonferroni-adjusted) revealed that for both B strains, IgG levels
significantly increased from baseline to four weeks post-vaccination (B/Brisbane: Mdiff(log) =
0.24, p < .001; B/Phucket: Mdiff(log) = 0.48, p <.001) and from four to 16 weeks post-
vaccination (B/Brisbane: M diff(log) = 0.14, p = .016; B/Phucket: Mdiff(log) = 0.24, p = .014). For
both A strains, IgG levels were significantly higher from baseline at both 4 and 16 weeks
post-vaccination (A/Hong-Kong: four weeks - Mdiff(log) = 0.34, p < .001; 16 weeks - Mdiff(log)
= 0.24, p < .001; A/Michigan: four weeks - Mdiff(log) = 0.40, p <.001; 16 weeks - Mdiff(log) =
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0.33, p < .001), but did not significantly differ between four and 16 weeks post-vaccination
(A/Hong-Kong: Mdiff(log) = -0.10, p = .267; A/Michigan: Mdiff(log) = -0.08, p = .250).
One way analyses of covariance showed that after adjusting for baseline antibody
levels, mean post-vaccination antibody levels were not statistically significantly different
between groups [A/Hong-Kong: four weeks - F(1, 99) = 0.61, p = .438, partial η2 = .006,
90% CI (.000, .055); 16 weeks - F(1, 95) = 0.43, p = .516, partial η2 = .004 , 90% CI (.000,
.051); A/Michigan: four weeks - F(1, 99) = 0.18, p = .671, partial η2 = .002 , 90% CI (.000,
.038); 16 weeks - F(1, 94) < 0.01, p = .980, partial η2 < .001 , 90% CI (.000, .000);
B/Brisbane: four weeks – F(1, 99) = 0.69, p = .409, partial η2 = .007 , 90% CI (.000, .057);
16 weeks - F(1, 95) = 0.79, p = .377, partial η2 = .008 , 90% CI (.000, .062); B/Phuket: four
weeks - F(1, 99) = 0.02, p = .892, partial η2 < .001 , 90% CI (.000, .008); 16 weeks - F(1,
95) = 0.64, p = .426, partial η2 = .007, 90% CI (.000, .058)] although point-estimates for all
effect sizes were in the predicted direction, favouring the positive mood intervention over
neutral control (see Figure 2). The only exception to this was in per protocol analyses, for
A/Michigan IgG levels at 16 weeks post-vaccination.
Influence of trait measures on IgG outcomes. To examine the role of trait
psychological characteristics and health status on IgG responses to vaccination, irrespective
of group assignment, a series of linear regression models were performed. These showed trait
positive affect was a significant independent predictor above pre-intervention IgG levels and
condition of B/Phuket IgG levels at 16 weeks post-vaccination [β = .172, p = .045. Model:
F(3, 86) = 18.30, p < .001, R2 = .390, ΔR2 = .029, ΔF (1, 86) = 4.15, p = .045]. Trait negative
affect significantly predicted the B/Phuket IgG levels at 4 weeks post-vaccination [β = .148, p
= .037. Model: F(3, 87) = 39.00, p < .001, R2 = .559, ΔR2 = .022, ΔF(1, 87) = 4.48, p = .037].
Both trait positive affect and optimism were predictive of B/Brisbane IgG levels at 16 weeks
post-vaccination [trait positive affect: β = .147, p = .033. Model: F(3, 86) = 44.71, p < .001,
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R2 = .596, ΔR2 = .021, ΔF(1, 86) = 4.71, p = .033; trait optimism: β = .132, p = .049. Model:
F(3, 87) = 47.51, p < .001, R2 = .621, ΔR2 = .017, ΔF(1, 87) = 3.99, p = .049] when
considered individually, but when entered simultaneously neither were significant
independent predictors. In per-protocol analyses, these trait predictors of B/Brisbane IgG at
16 weeks post-vaccination were not statistically significant (trait positive affect: β = .133, p =
.055. Model: F(3, 84) = 44.19, p < .001, R2 = .612, ΔR2 = .018, ΔF(1, 84) = 3.80, p = .055;
trait optimism: β = .115, p = .089. Model: F(3, 85) = 46.95, p < .001, R2 = .624, ΔR2 = .013,
ΔF(1, 85) = 2.95, p = .089).
Feasibility Measures
As shown in Figure 1, participant uptake was 9.4%. Other data on feasibility captured
during the trial also suggested that most trial activities were well tolerated by participants.
The only exception to this was the collection of saliva samples, which participants reported
difficulties with and resulted in 21% of participants failing to produce samples. There were
only three noted protocol violations and high levels of participant retention. Healthcare usage
attributable to influenza-like symptoms during the six months were similar between groups
(see supplementary appendix).
Discussion
The primary aim of this trial was to examine whether a brief intervention was able to
enhance positive mood at the time of vaccination in a clinical context. Secondary aims
included exploratory analyses of the effects of the intervention on non-specific and influenza-
specific immunity. Below, we discuss our findings in relation to each of these outcomes, as
well as exploring the feasibility of a future larger trial.
Intervention Effects on Mood
With regard to mood outcomes, we observed that in a clinical setting the positive
mood intervention resulted in positive affect improvements, compared with a neutral control
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intervention. The increase in positive affect was seen across all our state affect measures
apart from the PANAS, for which negative affect scores decreased in both groups (though not
significantly in the neutral control arm) and positive affect scores showed no change in either
group. The reasons for the divergent effects the PANAS positive affect subscale are unclear.
One explanation for this may relate to the orthogonal nature of the PANAS dimensions,
which were devised to be quasi-independent (Watson, 1988). As such, the positive affect
subscale does not include many adjectives typically associated with positive mood (e.g.,
happy, cheerful), but which were perhaps better captured in the other state affect measures
included in this trial. We further note that in a recent review we conducted of single session
interventions and immunity (Ayling et al., under review), all interventions that showed
significant improvements in PANAS subscales were considerably longer (≥1 hour) than the 
intervention examined here (e.g., Kiecolt-Glaser et al., 2008; Kreutz, Bongard, Rohrmann,
Hodapp, & Grebe, 2004).
That significant improvements in state affect were observed for the other measures is
particularly noteworthy given that participants showed high mean levels of positive affect
pre-intervention. This introduced the possibility of a ceiling effect (i.e., limiting the potential
for large improvements in state affect). Indeed, it is worth noting that the largest
improvements in state affect were observed in participants with higher levels of trait negative
affect at baseline. These participants also scored lower on all pre-intervention state affect
measures (all p’s <.05). Thus, the observed moderation may simply be due to the fact these
individuals had greater scope for their scores to increase following the intervention.
Intervention Effects on Non-specific Immunity
To explore whether the positive mood intervention resulted in any rapid changes to a
non-specific aspect of immunity, we measured secretory IgA levels pre- and post-
intervention. We observed significant increases in secretory IgA secretion among participants
MOOD AND INFLUENZA VACCINATION IN OLDER ADULTS 22
viewing the positive mood intervention. However, we saw a similar secretory IgA increase in
the neutral control group indicating, in this case, that any secretory IgA changes cannot be
attributable to a positive mood increase, and is likely best explained as an artefact of the
research process common to both groups. Given that PANAS negative affect scores
decreased from before to after the intervention in both groups (though this did not reach
statistical significance in the control group [Z = -1.93, p = .053, r = -.27]) we speculate that
the observed increase in secretory IgA levels across groups could reflect some form of
relaxation effect. Rest alone has previously been shown to result in increases in secretory IgA
levels (Donoyama & Shibasaki, 2010) therefore it may be that just the act of sitting quietly
and viewing a 15 minute video was sufficient to result in these changes. Notably, many prior
studies reporting an increase in secretory IgA concentration following positive mood
induction have adopted cohort or crossover designs without a neutral control group (e.g.,
Burns, Harbuz, Hucklebridge, & Bunt, 2001; Lefcourt, Davidson-Katz, & Kueneman, 1990).
In contrast, studies with control groups similar to ours typically show a similar pattern of
findings (e.g., Donoyama, Munakata, & Shibasaki, 2010; Donoyama & Shibasaki, 2010).
Collectively, these findings highlight the importance of future studies of secretory IgA and
mood including neutral control conditions, to avoid the potentially erroneous attribution of
secretory IgA changes to increases in positive mood.
Intervention Effects on Vaccine-specific Immunity
In examining the intervention effects on antibody responses to a quadrivalent
influenza vaccination, we observed no statistically significant differences between
participants who viewed the positive affect intervention to the neutral control group. This is
not surprising given that the trial was not powered for this outcome. Instead our aim was
exploratory, in that we sought to determine if there was early evidence of an effect of the
intervention on immunity and to explore the feasibility of a subsequent, appropriately
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powered trial. In that regard, we observed that for most strains at both 4 and 16 weeks post-
vaccination, the point-estimates of effect favoured the positive affect intervention and were
small. One interpretation of these findings is that they suggest that the intervention, whilst
demonstrating an effect on positive mood, is unlikely to result in an effect on antibody
responses of sufficient magnitude to be clinically relevant. But such a conclusion should be
interpreted in the context of two further issues. First, it could be argued that any effect in
clinical practice could potentially be larger than reported here. Our design included an active
neutral control as the comparison arm, rather than usual care (which would have been no
stimuli). This may have served to attenuate any observed between group differences on mood
and, in turn, on immune outcomes. Second, while we note due caution is warranted in over-
extrapolating effect size estimations from pilot trials (Bell & Julious, 2018; Kraemer, Mintz,
Noda, Tinklenberg, & Yesavage, 2015; Leon, Davis, & Kraemer, 2011), effect sizes of the
magnitude observed here are not necessarily trivial when the intervention is produced at low
cost and could be implemented at high volume. Even modest improvements to vaccine-
related clinical outcomes could be of substantial benefit to patients and the health service,
given the large number of vaccine recipients annually. Indeed, other low-cost high-volume
interventions have been widely adopted in clinical practice for the purpose of preventing
disease, even where effect sizes are relatively small (e.g., statins for the prevention of major
cardiovascular events: d = 0.15; Leucht, Helfer, Gartlehner, & Davis, 2015). We propose,
therefore, that further research is warranted involving trials in which changes in antibody
levels are the primary outcome and the comparator arm is usual care. Only then will we be
able to determine definitively if interventions that enhance positive mood are able to enhance
vaccine effectiveness and reduce the burden of disease.
In terms of the relationship between positive affect and antibody responses to
vaccination more broadly, we found across the entire sample, that higher levels of trait
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positive affect were also associated with significantly larger antibody responses to the
influenza vaccination (at least for the B strains of the vaccine). This replicates prior findings
demonstrating associations between trait, or long-term, positive affect and antibody responses
to vaccination (Ayling et al., 2018; Marsland et al., 2006). Mechanisms underpinning this
association continue to be elucidated and likely include both direct effects of the central
nervous system on immune function (Marques-Deak et al., 2005; Pressman & Cohen, 2005)
and indirect pathways. Whether these pathways can be leveraged to improve vaccine-related
outcomes in older adults remains a further avenue for researchers to explore.
Feasibility of a Larger Trial
This study supports the feasibility of conducting a future larger trial of the
intervention, potentially including an examination of effects on non-surrogate clinical
endpoints. The vast majority of participants receiving their allocated intervention as intended,
and high retention rates were observed across all follow-ups. While the uptake rate (9.4%) in
this trial was consistent with our prior studies in this area (Ayling et al., 2018) that have also
relied on a low-intensity recruitment approach (i.e., single invitation letter), there remains the
potential to improve these uptake rates with a more intensive approach. Evidence based
strategies for boosting recruitment rates which could be considered include telephone
reminders to non-responders and in-person patient screening and recruitment approaches
(Ngune, Moyez, Dadich, Lotriet, & Sriram, 2012; Treweek et al., 2018). Implementing such
strategies would likely be beneficial in increasing uptake rates in a future larger trial.
Limitations and Strengths
It is important to acknowledge that our results here relate to a quadrivalent egg-
derived influenza vaccine, and we do not know whether these findings will generalise to
future vaccines in an evolving landscape of approved influenza vaccines for use in older
adults. For example, the 2018/19 influenza vaccination season saw the introduction of an
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adjuvanted trivalent vaccine in the NHS (Wise, 2018), and the European Medicine Agency
(2018) recently approved cell-based quadrivalent and high-dose egg-derived trivalent
vaccines for use in 2019/20. Further research is needed to establish whether any benefits of a
brief positive mood intervention prior to vaccination are evident with different vaccine
formulations.
We also note that our sample were self-selecting, and therefore may not be entirely
representative of the older adult population. For the majority of demographic variables
assessed, we were successful in recruiting across a broad spectrum of older adults. However,
one concern is the lack of ethnic diversity of the recruited sample, which was almost
exclusively made up of those who identified as White-British. Moving towards a larger trial,
the adoption of recommendations for increasing ethnic minority adults into clinical research
(e.g., Areán, Alvidrez, Nery, Estes, & Linkins, 2003; Areán & Gallagher-Thompson, 1996)
will need to be considered.
This is the first trial to examine the effects of a brief positive mood intervention
administered prior to a quadrivalent influenza vaccine in primary care. We adopted a
controlled, single-blinded study design and made attempts to minimise the effects of demand
characteristics, by concealing aspects of the research from participants, namely by not
highlighting there were two groups, one of which was a neutral control. However,
participants were aware the study was examining the relationship between mood and
influenza vaccination responses. As such, we cannot rule out the possibility that the observed
effects on self-reported mood outcomes are influenced by this knowledge. Relatedly, while
steps were taken to keep researchers blind to participant allocation, due to common reactions
of participants to the positive mood intervention (e.g., laughter) it is possible that researchers
could have inferred group assignment for some participants. As the main outcome measures
were either participant reported immediately post-intervention (state affect), or machine-read
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optical absorbance values (immune), any lack of researcher blinding is unlikely to have
influenced the study findings.
Concluding Remarks
A brief 15-minute intervention resulted in significant improvements in positive mood
in older adults prior to receiving their annual influenza vaccination. Point-estimates of effects
on antibody responses indicated that effects on antibody were in the predicted direction.
Further research is now needed to establish whether a brief intervention could act as a low-
cost, high volume method for enhancing the effectiveness of influenza vaccination in older
people.
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Figure 1: Flow Diagram of Participants
Expressed Interest in
participation (n=129)
 Deceased (n=1)
 Did not attend no reason given
(n=2)
Lost to follow-up (n=1)
 Forgot Appointment (n=1)
Allocated to intervention (n=52)
 Received allocated intervention (n=52)
Lost to follow-up (n=0)
Allocated to control (n=51)
 Received allocated intervention (n=51)
Analysed – Intention to treat (n=51)
Analysed – Per-Protocol Analysis (n=49)
Randomized (n=103)
Invited (n=1131)
Consented into the study
(n=106)
 Declined to participate (n=6)
 Unable to attend sessions (n=5)
 Did not meet inclusion criteria
(n=2)
 Unable to contact (n=10)
Lost to follow-up (give reasons) (n=3)
 Did not attend no reason given (n=3)
Lost to follow-up (give reasons) (n=2)
 Did not attend no reason given (n=3)
4 Weeks Follow-Up
16 Weeks Follow-Up
MOOD AND INFLUENZA VACCINATION IN OLDER ADULTS 35
Figure 2: Antigen specific IgG responses to vaccination by group. Bars are antilog
transformed pre-vaccination IgG adjusted-means. Error bars are 95% confidence intervals.
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Table 1: Participant demographics by study arm+
Variable Positive
Mood
Intervention
Neutral
Control
Test for Between-Condition
Differences
Age - yr 72.6 (4.6) 73.3 (5.1) t(100) = 0.71, p = .480
Female sex – n (%) 22 (42.3) 30 (58.8) χ2(1) = 3.19, p = .074
White Ethnicity – n (%) 51 (98.1) 48 (94.1) χ2(2) = 1.05, p = .591
Marital Status – n (%) χ2(4) = 6.57, p = .161
Married 34 (65.4) 29 (56.9)
Single, never married 0 (0) 3 (5.9)
Separated/divorced 9 (17.3) 4 (7.8)
Widowed 4 (7.7) 8 (15.7)
Cohabiting 3 (5.8) 3 (5.9)
Did not respond 2 (3.8) 4 (7.8)
Highest Level of Education – n (%)  χ2(3) = 3.08, p = .380
School 37 (71.2) 40 (78.4)
Undergraduate 2 (3.8) 0 (0)
Postgraduate 0 (0) 1 (2.0)
Other 8 (15.4) 8 (15.7)
Did not respond 5 (9.6) 2 (3.9)
Living Independently – n (%) 47 (90.4) 49 (98.0) χ2(1) = 2.67, p = .102
Highest Ever Total Household Income – n (%) χ2(4) = 1.80, p = .773
≤ £14,999 17 (32.7) 16 (31.4)  
£15,000–£24,999 16 (30.8) 17 (33.3)
£25,000–£34,999 8 (15.4) 4 (7.8)
£35,000–£49,000 7 (13.5) 5 (0.8)
£50,000–£74,999 1 (1.9) 2 (3.9)
£75,000–£99,000 0 (0) 0 (0)
≥ £100,000 0 (0) 0 (0)  
Did Not Respond 3 (5.8) 7 (13.7)
Current Smoker – n (%) 4 (7.7) 4 (7.8) χ2(1) = 0.003, p = .954
Total Health Status 555.7
(175.1)1
555.1 (169.9) t(95) = -0.02, p = .988
Trait Positive Affect (PANAS) 33.5 (8.6) 33.8 (8.1) U = 1104.5, Z = -.15, p =.878
Trait Negative Affect (PANAS) 15.2 (6.7) 15.5 (6.4) U = 1013.5, Z = -.32, p =.753
Trait Optimism 16.0 (4.8) 15.3 (4.5) t(94) = -.80, p = .424
Trait Emotional Reactivity 39.9 (17.2) 41.3 (16.0) t(93) = .71, p = .481
Pre-Vaccination IgG
A/Michigan 187.2 (112.4) 156.6 (103.1) t(101) = -1.84, p = .069‡
A/Hong Kong 238.0 (119.9) 241.0 (158.1) t(101) = -0.46, p = .646‡
B/Brisbane 107.0 (54.1) 118.9 (78.7) t(92.32) = 0.19, p = .850‡
B/Phuket 144.4 (85.1) 183.2 (146.2) t(101) = 1.01, p = .313‡
+Mean (standard deviation) unless otherwise specified
‡ Based on log-transformed values
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Table 2: Pre- and Post-Intervention Momentary Affect and S-IgA scores by group [Mean (SD)]
Variable
Positive Mood Condition(n=52) Neutral Control Condition
(n=51)
Pre-Intervention Post-Intervention Pre-
Intervention
Post-
Intervention
Slider-valence 79.5 (19.2) 87.4 (15.7) 80.5 (18.1) 79.8 (20.8)
Slider-arousal 79.9 (19.0) 83.7 (16.8) 80.9 (20.1) 79.8 (20.3)
Pictorial 3.7 (1.5) 4.7 (1.1) 4.0 (1.5) 4.0 (1.5)
Positive Affect
(PANAS)
34.3 (7.3) 35.0 (8.4) 34.6 (7.2) 35.0 (7.6)
Negative Affect
(PANAS)
12.3 (4.0) 11.1 (3.0) 12.3 (4.0) 11.4 (2.3)
Salivary IgA (g/min)
+
81.0 (76.4) 116.7 (107.5) 94.1 (94.2) 144.7 (142.5)
+Based on positive mood condition: n=46; neutral control condition: pre-intervention n=42, post
intervention n=41
Supplementary Table 1: Number of participants with data for measures by group.
Positive Mood Condition
(n=52 assigned)
Neutral Control Condition
(n=51 assigned)
State Affect Measures
Pre-intervention slider-valence 49 51
Post-intervention slider-valence 52 51
Pre-intervention slider-arousal 49 51
Post-intervention slider-arousal 52 51
Pre-intervention PA 52 51
Post-intervention PA 52 49
Pre-intervention NA 52 51
Post-intervention NA 52 51
Pre-intervention Pictorial 50 49
Post-intervention pictorial 50 51
Trait Measures
Total Health Status 49 48
Trait PA 50 45
Trait NA 49 43
Trait Optimism 50 46
Trait Emotional Reactivity 47 48
Immune Measures
Pre-intervention S-IgA 46 42
Post-intervention S-IgA 46 41
Baseline B/Brisbane IgG 52 51
4 Weeks Post-Vaccination B/Brisbane IgG 51 51
16 Weeks Post-Vaccination B/Brisbane IgG 49 49
Baseline B/Phuket IgG 52 51
4 Weeks Post-Vaccination B/Phuket IgG 51 51
16 Weeks Post-Vaccination B/Phuket IgG 49 49
Baseline A/Hong-Kong IgG 52 51
4 Weeks Post-Vaccination A/Hong-Kong IgG 51 51
16 Weeks Post-Vaccination A/Hong-Kong IgG 49 49
Baseline A/Michigan IgG 52 51
4 Weeks Post-Vaccination A/Michigan IgG 51 51
16 Weeks Post-Vaccination A/Michigan IgG 48 49
Supplementary Table 2: Healthcare Utilisation attributable to influenza-like symptoms during six months
post-vaccination
Experimental Control
Consultations
GP 14 13
Nurse 1 1
Out of Hours\Telephone 7 3
Emergency Department 1 1
Antibiotic Prescriptions 6 9
Additional Investigations (e.g., X-ray) 4 3
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Section/Topic
Item
No Checklist item
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on page No
Title and abstract
1a Identification as a randomised trial in the title 1
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) 2
Introduction
Background and
objectives
2a Scientific background and explanation of rationale 3-5
2b Specific objectives or hypotheses 5
Methods
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 5-6
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons 14
Participants 4a Eligibility criteria for participants 6
4b Settings and locations where the data were collected 6-7
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were
actually administered 8-9
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they
were assessed 9-13
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Sequence
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were analysed for the primary outcome
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2, Figure 1
13b For each group, losses and exclusions after randomisation, together with reasons 15, Figure 1
Recruitment 14a Dates defining the periods of recruitment and follow-up 5
14b Why the trial ended or was stopped N/A
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group Table 1
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was
by original assigned groups
15, Table 1,
Table 2
Outcomes and
estimation
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its
precision (such as 95% confidence interval) 16-20
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended N/A
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing
pre-specified from exploratory 16-20
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) N/A
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 24-25
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 22-25
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 20-25
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Registration 23 Registration number and name of trial registry 2
Protocol 24 Where the full trial protocol can be accessed, if available N/A
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